Antitussive offers convenient twice-daily dosing

News
Article

The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.

Recent Videos
Related Content
FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

Lauren Biscaldi, MS, Managing Editor
October 23rd 2024
Article

Abrysvo is the only RSV vaccine approved for use in this age group.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease

FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease

Kevin W. Chamberlin, PharmD, FASCP;Molly Csere, PharmD
October 15th 2024
Article

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

FDA Approves Ceftobiprole Medocaril Sodium for 3 Indications

FDA Approves Ceftobiprole Medocaril Sodium for 3 Indications

Jenny Zhao, PharmD;Kevin W. Chamberlin, PharmD, FASCP
October 14th 2024
Article

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

FDA Roundup: Hemophilia B Therapy, Stelara Biosimilar Approval

FDA Roundup: Hemophilia B Therapy, Stelara Biosimilar Approval

Killian Meara
October 11th 2024
Article

Check out important updates from the FDA for the week of October 7.

FDA Approves First Weekly Subcutaneous Therapy for Hemophilia B

FDA Approves First Weekly Subcutaneous Therapy for Hemophilia B

Lauren Massaro
October 11th 2024
Article

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

© 2024 MJH Life Sciences

All rights reserved.